Filing Flows › Regenxbio (RGNX) › Q4 2025
Regenxbio (RGNX) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 5, 2026
Regenxbio (RGNX) reported revenue of $30.3M for the fourth quarter 2025 (Q4 2025), +43% from a year earlier and +2% from the quarter before. Operating margin was -190.0%, net loss $67.1M (221.3% of revenue).
Regenxbio, Q4 2025: revenue $30.3M (+43% year over year), operating margin -190.0%, net loss $67.1M, operating cash flow −$52.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $30.3M | +2% | +43% |
| Operating profit | −$57.6M | — | — |
| Net earnings | −$67.1M | — | — |
| Operating cash flow | −$52.3M | — | — |
What changed
Revenue was $30.3M in Q4 2025, up 43% year over year and up 2% from the previous quarter. License and Service was the largest line at 89% of revenue.
Operating costs exceeded revenue by $57.6M, an operating margin of -190.0%. Total costs grew 21% against revenue growth of 43%. The quarter ended with a net loss of $67.1M, wider than the previous quarter's $61.9M loss.
Operating cash flow was −$52.3M. Non-cash charges added back $3.9M of depreciation and amortization and $8.4M of share-based compensation. Working capital and other items added $2.6M. Capital expenditures of $508K exceeded it, leaving free cash flow of −$52.8M.
Questions
What was Regenxbio's revenue in the fourth quarter 2025?
Regenxbio (RGNX) reported revenue of $30.3M for the fourth quarter 2025 (Q4 2025), +43% from a year earlier and +2% from the quarter before.
Was Regenxbio profitable in the fourth quarter 2025?
Operating loss was $57.6M (-190.0% of revenue) and net loss $67.1M.
Source: Regenxbio 10-K on SEC EDGAR.